Company: PRTA
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001559053-25-000044
Chunk: 0

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 0
---
 561,365  
  Share-based compensation                                                                                               12,383                                                     12,383  
  Issuance of ordinary shares upon exercise of stock options                  38,338      —           890                                              890                                  
  Net loss                                                                                                                              ( 72,239)                                ( 72,239)  
  Balances at March 31, 2024                                              53,720,455      537                         1,554,132      ( 1,052,270)                                  502,399  
  Share-based compensation                                                                                               12,041                                                     12,041  
  Issuance of ordinary shares upon exercise of stock options                  51,390      1           590                                              591                                  
  Net income                                                                                                                               66,886                                   66,886  
  Balances at June 30, 2024                                               53,771,845      538                         1,566,763        ( 985,384)                                  581,917  
  Share-based compensation                                                                                               11,020                                                     11,020  
  Issuance of ordinary shares upon exercise of stock options                  35,887      —           426                                              426                                  
  Issuance of ordinary shares upon vesting of restricted stock units           1,000      —           —                                                —                                    
  Net loss                                                                                                                              ( 59,001)                                ( 59,001)  
  Balances at September 30, 2024                                          53,808,732      $           $               1,578,209      ( 1,044,385)      $                           534,362  

See accompanying Notes to Condensed Consolidated Financial Statements.

Notes to the Condensed Consolidated Financial Statements

(unaudited)

1. Organization

Description of Business

Prothena Corporation plc (“ Prothena” or the “ Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases.

Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. These programs include prasinezumab for the potential treatment of Parkinson’s disease and other related synuclein